Author Archives: Azaharuddin Mohammad

Dr Marshall is a Senior Research Fellow at Queen’s University Belfast and was the first early career researcher recruited to the editorial board of Access Microbiology, a new OA journal. Read More

In his interview on peer review, Craig Raybould highlights key aspects such as publication operations, open access, and their impacts on the value chain, offering insights into these critical areas. Read More

Peer review is essential to the publication process, offering a seal of approval that helps academics build their reputations. It has become a cornerstone of scholarly publishing, validating and revealing. Read More

There are currently no compliance mandate around ESG reporting, especially for private companies, and such reporting is voluntary. While many large companies report on ESG as part of CSR effectively. Read More

The scholarly publishing industry has undergone significant changes over the last few decades, and with the pandemic outbreak, it became significant for the scholarly communication sector to understand and responds. Read More

Common accessibility standards, such as Web Content Accessibility Guidelines 2.1 and EPUB Accessibility 1.0, support accessible publishing. Publishers can also use the Marrakesh Treaty to facilitate access to works for. Read More

Enterprises tend to employ data from external sources in their data strategy to convert insights into financial gain as they mature in their data journey. This external data comes in. Read More

The Society’s first fully digital conference covered advanced topics in scholarly publishing, communication, and professional development. It emphasized education, collaboration, and networking to enhance skills and opportunities for its members. Read More

In the wake of the pandemic’s widespread impact, the scholarly publishing community provided access to materials online. Publishers worldwide united to offer research materials for free through various platforms effectively. Read More

The COVID-19 has triggered a rush of clinical trials to discover vaccines, threatening the continuity and success of non-COVID-19 drug discovery pipelines. This guide will help you learn to mitigate. Read More